Boehringer Ingelheim announced the grand opening of its newly expanded research and development facility in Athens, Georgia. As the largest animal health company in Georgia, this Boehringer ...
Sunir Garg, MD, shares insights on new data on aflibercept 8 mg, faricimab, and the impact of social determinants of health, ...
One of the primary factors fueling the growth of the DOACs market is the rapid uptake and expected utilization within the ...
QUANTRO Therapeutics and IMP enter into research collaboration to accelerate transcriptomic drug discovery. Strategic partnership with the Research Institute of Molecular Patholog ...
The CEO of pharmaceuticals giant Roche has urged authorities to block the takeover of contract drug manufacturer Catalent by ...
The Progressive Fibrosing Interstitial Lung Disease (PF-ILD) market is currently valued at USD 4,742.2 Million in 2023 and is ...
Asthma affects approximately 262 million people globally, with the number of asthma incidents having increased by around 15% ...
Progressive pulmonary fibrosis (PPF) is an increasingly recognised condition, defined in 2022 to address the progression of ...
Paige Mahaney, Ph.D. Chief Scientific Officer Mahaney Brings More Than 25 Years of Pharmaceutical and Biotech Experience ...
Boehringer Ingelheim had previously explored Ofev as a treatment for ... this is also a very important and valuable ...
The lifetime risk of an unexpected and sudden death from a cardiovascular cause in the absence of pre-existing heart disease—known as sudden cardiac death—is more than 4 times higher for people with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback